Cardium Therapeutics (NYSE MKT: CXM), a health sciences and regenerative medicine company focused on unlocking the value in medical assets, has developed a unique gene therapy targeting heart disease that takes a different approach than stent-makers like Medtronic, Inc. (NYSE: MDT) or molecular therapy companies like Amgen Inc. (NASDAQ: AMGN). Generx, which is now patented